Rakuten Securities Inc. Increases Stake in Pfizer Inc. $PFE

Rakuten Securities Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 77.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,104 shares of the biopharmaceutical company’s stock after purchasing an additional 21,058 shares during the quarter. Rakuten Securities Inc.’s holdings in Pfizer were worth $1,225,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Curio Wealth LLC raised its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at approximately $30,000. True Wealth Design LLC lifted its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.6%

Shares of PFE opened at $25.56 on Thursday. The company’s 50-day simple moving average is $25.31 and its 200-day simple moving average is $24.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The stock has a market capitalization of $145.32 billion, a PE ratio of 14.86 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. HSBC reissued a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.